{"nctId":"NCT01295814","briefTitle":"Efficacy Study of Adalimumab to Treat Interstitial Cystitis","startDateStruct":{"date":"2011-03"},"conditions":["Interstitial Cystitis"],"count":43,"armGroups":[{"label":"adalimumab","type":"EXPERIMENTAL","interventionNames":["Drug: Adalimumab"]},{"label":"Inactive drug","type":"PLACEBO_COMPARATOR","interventionNames":["Other: inactive drug"]}],"interventions":[{"name":"Adalimumab","otherNames":["Humira"]},{"name":"inactive drug","otherNames":["placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males or females ≥18 and ≤ 65 years of age previously diagnosed with Interstitial Cystitis\n* Currently have symptoms of urinary urgency, frequency or pain for more than 6 months\n* Urinating at least 7 times a day or having some urgency or pain (measured on linear analog scales)\n* Must be post-menopausal or surgically sterile or willing to use an adequate form of birth control\n* Not pregnant or lactating\n* Capable of voiding independently\n* Willing to provide informed consent to participate\n\nExclusion Criteria:\n\n* Have symptoms that are presently relieved on other medications for interstitial cystitis\n* Have absence of nocturia\n* Have symptoms that are relieved by antimicrobials or antibiotics.\n* Have a body mass index (BMI) of \\>39 kg/m2\n* Have uncontrolled hypertension\n* Have Type I or type 2 diabetes\n* Have active Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) infection, or who are known carriers (Hepatitis B) at Screening\n* Have a positive tuberculosis test at screening\n* Have had a urinary tract infection for 6 weeks\n* Have had bacterial cystitis in previous 3 months\n* Have had previous exposure to Humira® (adalimumab)\n* Have taken investigational medication within 30 days of screening\n* Have any other condition/disease which, in the opinion of the investigator, could compromise subject safety or confound the interpretation of study results\n* Are unable or unwilling to comply with protocol requirements","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"O'Leary-Santa Interstitial Cystitis Symptom Index and Problem Index (OSPI) Score","description":"Improvement in the O'Leary Sant Symptom and Problem Index from baseline to week 12 Total scores on a scale range: 0-36 (0, meaning no symptoms to 36, meaning the most severe symptoms)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":"4.9"},{"groupId":"OG001","value":"27.8","spread":"3.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":"10.7"},{"groupId":"OG001","value":"19.9","spread":"7.5"}]}]}]},{"type":"SECONDARY","title":"Interstitial Cystitis Symptom Index (ICSI)","description":"Improvement in O'Leary Sant Interstitial Cystitis Symptom Index (ICSI) Total scores on a range scale: 0-20 (0, meaning no symptoms, to 20, meaning the most severe symptoms)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":"3.1"},{"groupId":"OG001","value":"14.0","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"5.7"},{"groupId":"OG001","value":"10.0","spread":"4.2"}]}]}]},{"type":"SECONDARY","title":"Interstitial Cystitis Problem Index (ICPI)","description":"Improvement in O'Leary Sant Interstitial Cystitis Problem Index (ICPI) Total scores on a scale: 0-16 (0, meaning no symptoms, to 16, meaning the most severe symptoms)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":"2.2"},{"groupId":"OG001","value":"13.8","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":"5.1"},{"groupId":"OG001","value":"9.9","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Pelvic Pain Urgency/Frequency (PUF) Score","description":"Pelvic Pain, Urgency/Frequency Symptom Scale Total scores on a scale range: 0-35 (0, meaning no symptoms, to 35, meaning the most severe symptoms)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"3.9"},{"groupId":"OG001","value":"24.6","spread":"4.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":"8.7"},{"groupId":"OG001","value":"18.3","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"Global Response Assessment (GRA)","description":"Percent(%) of patients who reported 50% or greater overall improvement in their condition.\n\nScore on a scale range (improvement 0%-100%)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["Upper Respiratory Infection","Pain","Diarrhea","Headache","Urinary Tract Infection"]}}}